| Literature DB >> 34914540 |
M Gordon Joyce1,2, Hannah A D King1,2,3, Ines Elakhal-Naouar2,4, Aslaa Ahmed5, Kristina K Peachman4, Camila Macedo Cincotta2,4, Caroline Subra1,2,3, Rita E Chen6,7, Paul V Thomas1,2, Wei-Hung Chen1,2, Rajeshwer S Sankhala1,2, Agnes Hajduczki1,2, Elizabeth J Martinez1,2, Caroline E Peterson1,2, William C Chang1,2, Misook Choe1,2, Clayton Smith8, Parker J Lee1,2, Jarrett A Headley1,2, Mekdi G Taddese1,2, Hanne A Elyard9, Anthony Cook9, Alexander Anderson3,10, Kathryn McGuckin Wuertz3, Ming Dong1,2,3, Isabella Swafford1,2,3, James Brett Case6, Jeffrey R Currier5, Kerri G Lal1,2,3, Sebastian Molnar1,2,3, Manoj S Nair11, Vincent Dussupt1,2,3, Sharon P Daye12, Xiankun Zeng13, Erica K Barkei14, Hilary M Staples15, Kendra Alfson15, Ricardo Carrion15, Shelly J Krebs1,2,3, Dominic Paquin-Proulx1,2,3, Nicos Karasavva2,4, Victoria R Polonis3, Linda L Jagodzinski4, Mihret F Amare1,2, Sandhya Vasan1,2,3, Paul T Scott1, Yaoxing Huang11, David D Ho11, Natalia de Val8, Michael S Diamond6,7,16, Mark G Lewis9, Mangala Rao3, Gary R Matyas3, Gregory D Gromowski5, Sheila A Peel4, Nelson L Michael12, Diane L Bolton1,2,3, Kayvon Modjarrad1.
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019 (COVID-19). We developed and evaluated an adjuvanted SARS-CoV-2 spike ferritin nanoparticle (SpFN) vaccine in nonhuman primates. High-dose (50 μg) SpFN vaccine, given twice 28 days apart, induced a Th1-biased CD4 T cell helper response and elicited neutralizing antibodies against SARS-CoV-2 wild-type and variants of concern, as well as against SARS-CoV-1. These potent humoral and cell-mediated immune responses translated into rapid elimination of replicating virus in the upper and lower airways and lung parenchyma of nonhuman primates following high-dose SARS-CoV-2 respiratory challenge. The immune response elicited by SpFN vaccination and resulting efficacy in nonhuman primates supports the utility of SpFN as a vaccine candidate for SARS-causing betacoronaviruses.Entities:
Mesh：
Substances：
Year: 2022 PMID： 34914540 DOI： 10.1126/scitranslmed.abi5735
Source DB: PubMed Journal: Sci Transl Med ISSN： 1946-6234 Impact factor: 17.956